Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Genomic profiling SMM

Mark Bustoros • 13 Sep 2019
IMW 2019
Multiple Myeloma Rare Diseases Smoldering Myeloma

Mark Bustoros, MD, Dana-Farber Cancer Institute, Boston, MA, interviews with VJHemOnc at the International Myeloma Workshop (IMW) 2019, held in Boston, MA, and discusses how the genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression.

More from Mark Bustoros

1:30
Evolution in myeloma therapy
Mark Bustoros • 14 Oct 2021
4:15
Myeloma & precursor disorders: what does NGS reveal?
Mark Bustoros • 14 Oct 2021
1:28
Risk stratification models for smoldering myeloma
Mark Bustoros • 14 Oct 2021
3:38
Insights on genomic techniques in myeloma
Mark Bustoros • 14 Oct 2021

Related Videos

1:36
Identification of high-risk disease using Molecular profiling by Mymap
Gareth Morgan • 26 Feb 2016
2:33
Where do new drugs fit into the treatment landscape of multiple myeloma?
Joseph Mikhael • 5 Feb 2016
1:29
Treatment outcomes of elderly patients with AL Amyloidosis
Giampaolo Merlini • 4 May 2018
10:26
Myeloma 2016: Panel discussion on the application of genomics studies
Leif Bergsagel et al. • 14 Jun 2016
The content of VJHemOnc is intended for healthcare professionals